I3Y-MC-JPBX - ClinicalTrials.gov - NCT02450539
I3Y-MC-JPBX - ClinicalTrials.gov - NCT02450539
Key Requirements
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Participants must
Participant must have a confirmed diagnosis of stage IV Squamous NSCLC
Participant must have progressed during or after platinum-based chemotherapy
Participant must be fully active or if restricted in physically strenuous activity should be able to walk and carry out light work, e.g., light house work, office work
Participant must agree to use a reliable medically approved method of birth control
Participants must NOT
Participant must not have received prior treatment with docetaxel
Participant must not have received prior treatment with any cyclin dependent kinase (CDK) 4 and 6 inhibitor or participated in a clinical trial with a CDK 4 and 6 inhibitor where the treatment administered is not known
Participant must not be currently receiving treatment in a clinical trial involving an investigational product or non-approved use of a drug or device
Trial Summary
Conditions the trial is for
Non-small Cell Lung Cancer
What the trial is testing?
Abemaciclib (LY2835219), Docetaxel
Could I receive a Placebo?
no
Enrollment Goal
150
Trial Dates
August 2015 - July 2020
Trial Phase
2
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Participants must
Participant must have a confirmed diagnosis of stage IV Squamous NSCLC
Participant must have progressed during or after platinum-based chemotherapy
Participant must be fully active or if restricted in physically strenuous activity should be able to walk and carry out light work, e.g., light house work, office work
Participant must agree to use a reliable medically approved method of birth control
Participants must NOT
Participant must not have received prior treatment with docetaxel
Participant must not have received prior treatment with any cyclin dependent kinase (CDK) 4 and 6 inhibitor or participated in a clinical trial with a CDK 4 and 6 inhibitor where the treatment administered is not known
Participant must not be currently receiving treatment in a clinical trial involving an investigational product or non-approved use of a drug or device
Trial Summary
Conditions the trial is for
Non-small Cell Lung Cancer
What the trial is testing?
Abemaciclib (LY2835219), Docetaxel
Could I receive a Placebo?
no
Enrollment Goal
150
Trial Dates
August 2015 - July 2020
Trial Phase
2
Trial Locations
Hide locations not currently recruiting